

Title (en)  
METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS

Title (de)  
VERFAHREN UND ZUSAMMENSETZUNGEN NEUER TRIAZINVERBINDUNGEN

Title (fr)  
METHODES ET COMPOSITIONS FAISANT INTERVENIR DE NOUVELLES TRIAZINES

Publication  
**EP 1436266 A4 20041222 (EN)**

Application  
**EP 02799019 A 20020923**

Priority  
• US 0230177 W 20020923  
• US 32414701 P 20010921

Abstract (en)  
[origin: WO03024926A2] The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

IPC 1-7  
**C07D 251/44**; C07D 251/46; C07D 251/48; C07D 251/50; C07D 251/70; C07D 401/12; C07D 403/12; C07D 405/12; C07D 401/14; C07D 403/14; C07D 405/14; C07D 453/02; A61K 31/53; A61P 35/00; A61P 19/02; A61P 17/06

IPC 8 full level  
**A61K 31/35** (2006.01); **A61K 31/53** (2006.01); **A61K 31/5377** (2006.01); **A61P 19/02** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 43/00** (2006.01); **C07D 251/44** (2006.01); **C07D 251/46** (2006.01); **C07D 251/48** (2006.01); **C07D 251/50** (2006.01); **C07D 251/52** (2006.01); **C07D 251/70** (2006.01); **C07D 401/12** (2006.01); **C07D 401/14** (2006.01); **C07D 403/04** (2006.01); **C07D 403/12** (2006.01); **C07D 403/14** (2006.01); **C07D 405/12** (2006.01); **C07D 405/14** (2006.01); **C07D 409/14** (2006.01); **C07D 453/02** (2006.01); **C07D 471/08** (2006.01)

CPC (source: EP KR)  
**A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 251/44** (2013.01 - EP KR); **C07D 251/46** (2013.01 - EP); **C07D 251/48** (2013.01 - EP); **C07D 251/50** (2013.01 - EP); **C07D 251/52** (2013.01 - EP); **C07D 251/70** (2013.01 - EP); **C07D 401/12** (2013.01 - EP); **C07D 403/04** (2013.01 - EP); **C07D 403/12** (2013.01 - EP KR); **C07D 403/14** (2013.01 - EP); **C07D 453/02** (2013.01 - EP)

Citation (search report)  
• [A] WO 9931088 A1 19990624 - ABBOTT LAB [US]  
• [A] WO 0147897 A1 20010705 - PHARMACOPEDIA INC [US], et al  
• See references of WO 03024926A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

DOCDB simple family (publication)  
**WO 03024926 A2 20030327**; **WO 03024926 A3 20031211**; BR 0212895 A 20050510; CA 2461074 A1 20030327; CN 1578773 A 20050209; EA 009728 B1 20080228; EA 200400464 A1 20050224; EP 1436266 A2 20040714; EP 1436266 A4 20041222; IL 160984 A0 20040831; IS 7190 A 20040319; JP 2005511509 A 20050428; KR 20040088457 A 20041016; MX PA04002680 A 20040618; NO 20041187 L 20040519; NZ 532349 A 20070223; PL 369600 A1 20050502; RS 34004 A 20061027; ZA 200403009 B 20071227

DOCDB simple family (application)  
**US 0230177 W 20020923**; BR 0212895 A 20020923; CA 2461074 A 20020923; CN 02823240 A 20020923; EA 200400464 A 20020923; EP 02799019 A 20020923; IL 16098402 A 20020923; IS 7190 A 20040319; JP 2003528774 A 20020923; KR 20047004179 A 20020923; MX PA04002680 A 20020923; NO 20041187 A 20040322; NZ 53234902 A 20020923; PL 36960002 A 20020923; YU P34004 A 20020923; ZA 200403009 A 20040420